FCPM III Services B.V. has made a significant move by initiating a new position in Damora Therapeutics (NASDAQ: DMRA), acquiring 2,441,000 shares valued at approximately $65.63 million as of March 31, 2026. This investment represents 9.09% of the fund’s reportable U.S. equity assets under management, highlighting a strong conviction in the biotech firm’s potential.
The acquisition comes at a time when Damora Therapeutics has seen its stock surge nearly 700% over the past year, driven by its focus on developing small-molecule therapeutics for cancer and fibrotic diseases. With a robust cash position of $532.9 million, the company is well-positioned to fund its operations through 2029, even as it reported a widening net loss of $27.8 million in the first quarter. Investors are increasingly optimistic about upcoming clinical milestones, particularly the anticipated regulatory submission for its lead candidate, DMR-001.
For market professionals, FCPM’s substantial investment in Damora underscores a belief in the company’s transformative potential and future growth, despite its recent stock performance. This transaction may signal a broader trend of institutional interest in biotech firms with promising pipelines and solid financial backing.
Source: nasdaq.com